Background In the management of patients with differentiated thyroid carcinoma, direct
comparison of the presence of scintigraphic stunning after a diagnostic dose of 131 I with …

Detection of residual tissue after thyroidectomy for papillary or follicular thyroid carcinoma
may be performed using diagnostic imaging with either 123I or 131I. The former is often …

" Thyroid stunning" from diagnostic iodine-131 imaging prior to ablative therapy with 131 I for
well-differentiated thyroid carcinoma has been well reported, but documentation of the effect …

PURPOSE: To determine if stunning can be seen with a 185-MBq (5-mCi) dose of iodine
131 (131I) at diagnostic whole-body scanning and, if stunning is seen, determine if there is …

Differentiated thyroid cancer is treated by (near) total thyroidectomy followed by radioiodine
(131 I) ablation of the residual active tissue in the thyroid bed. Controversy remains …

Thyroid stunning is a radiobiological phenomenon. It may be defined as a temporary
suppression of iodine, trapping function of the thyrocytes and thyroid cancer cells as a result …

The use of 131I in doses of several mCi for scans can stun the thyrocytes and thyroid cancer
cells, whereas the usual dose (300 μCi) of 123I does not. We compared the diagnostic …

Context: Published studies of thyroid stunning due to preablation 131I scanning in the
treatment of differentiated thyroid cancer after thyroidectomy had shown inconsistent clinical …

Purpose To compare disease-specific survival and recurrence-free survival (RFS) after
successful 131 I ablation in patients with differentiated thyroid carcinoma (DTC) between …

Purpose This article examines the outcome of radioactive iodine ablation therapy for thyroid
cancer in high-risk patients and investigates background factors influencing ablation failure …